Upload
ledung
View
212
Download
0
Embed Size (px)
Citation preview
Table of ContentsSEARCH STRATEGY................................................................................................................................................................................................3
Table I: Characteristics of the included studies:...........................................................................................................................................................8
Table II: Outcomes (rate, 95% confidence interval) per vascular access type:..........................................................................................................27
Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:..........................................................................28
III.1: Arteriovenous fistula (AVF), unspecified location:......................................................................................................................................28
III.2: Upper arm AVF:........................................................................................................................................................................................... 30
III.3: Brachial- Basilic fistula:...............................................................................................................................................................................30
III.4: Brachial-brachial fistula:...............................................................................................................................................................................31
III.5: Brachial-Cephalic fistula:.............................................................................................................................................................................32
III.6: Forearm AVF:............................................................................................................................................................................................... 33
III.7: Radiocephalic fistula:....................................................................................................................................................................................34
III.8: Forearm basilic fistula:.................................................................................................................................................................................37
III.9: Lower extremity fistula:................................................................................................................................................................................37
III.10: Arteriovenous graft (AVG), unspecified location:......................................................................................................................................38
III.11: Upper arm graft:..........................................................................................................................................................................................39
III.12: Forearm graft:............................................................................................................................................................................................. 40
III.13: Axillary-Axillary graft:...............................................................................................................................................................................40
III.14: Lower extremity graft:................................................................................................................................................................................41
III.15: Tunneled cuffed catheter, unspecified location:..........................................................................................................................................41
III.16: Tunneled cuffed IJ/subclavian PermCath:...................................................................................................................................................42
1
III.17: Hybrid graft and catheter (HeRO):..............................................................................................................................................................42
Table IV: Average days to maturation:......................................................................................................................................................................44
Table V: Summary results of meta-analysis of included comparative studies per access types:................................................................................45
V.1: AVF, unspecified location:............................................................................................................................................................................45
V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:..........................................................................................47
V.3: Forearm AVF VS. Upper-arm AVF:..............................................................................................................................................................49
V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:.........................................................................................49
V.5: AVG, unspecified location VS. AVF, unspecified location:..........................................................................................................................50
V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:.........................................................................................51
References:................................................................................................................................................................................................................ 54
2
SEARCH STRATEGYOvid
Database(s): Embase 1988 to 2014 Week 45, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials October 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2014 Search Strategy:# Searches Results
1 exp Kidney Failure, Chronic/ 1224622 exp end stage renal disease/ 87207
3
("chronic kidney failure" or "chronic renal failure" or "end stage kidney disease" or "end stage kidney failure" or "end stage renal disease" or "end stage renal dysfunction" or "end stage renal failure" or "end stage renal impairment" or "end stage renal insufficiency" or "end-stage kidney disease" or "end-stage renal disease" or "end-stage renal failure" or ESRD or "stage 5 kidney disease" or "stage 5 renal disease").mp.
132847
4 or/1-3 1826145 exp hemodialysis/ 1613006 exp Renal Dialysis/ 208945
7
((dialys* adj (center* or centre*)) or "acetate free biofiltration*" or "blood dialys*" or "extracorporeal blood cleansing" or "extracorporeal dialys*" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or "kidney dialys*" or "peritoneal dialys*" or "renal dialys*").mp.
226829
8 or/5-7 2452299 (longterm or "long-term" or chronic*).mp. 329560810 8 and 9 111324
11
(((dialys* or "acetate free biofiltration*" or "extracorporeal blood cleansing" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or site or route or fistula* or catheter*) adj3 access*) or "Atrial graft*" or "Axillary axillary graft*" or "Brachial-basilic*" or "Brachial-brachial" or "Brachial-cephalic*" or "Cimino-radialcephalic*" or "Forearm basilic*" or "Forearm loop graft*" or HeRO or "Lower extremity fistula*" or "Lower extremity graft*" or permacath* or "perma-cath*" or "Upper arm graft*").mp.
24338
12 4 and 10 and 11 236913 exp evidence based medicine/ 733513
3
14 exp meta analysis/ 13886115 exp Meta-Analysis as Topic/ 3071716 exp "systematic review"/ 8137417 exp Guideline/ or exp Practice Guideline/ 34788018 exp controlled study/ 455482919 exp Randomized Controlled Trial/ 73840520 exp triple blind procedure/ 7521 exp Double-Blind Method/ 34681922 exp Single-Blind Method/ 5213723 exp latin square design/ 27724 exp Placebos/ 27105925 exp Placebo Effect/ 740526 exp comparative study/ 249376727 exp Cross-Sectional Studies/ 31950728 exp Cross-Over Studies/ 10274729 exp Cohort Studies/ 172554830 exp longitudinal study/ 109148331 exp retrospective study/ 88536832 exp prospective study/ 71714733 exp population research/ 6868634 exp observational study/ 6879735 exp clinical trial/ 175770636 clinical study/ 5504337 exp Evaluation Studies/ 21552138 exp Evaluation Studies as Topic/ 115944739 exp quantitative study/ 600740 exp validation studies/ 11699041 exp experimental study/ 1509842 exp quasi experimental study/ 212543 in vivo study/ 192702
4
44 exp panel study/ 38245 exp Pilot Projects/ 17501946 exp pilot study/ 17501947 exp prevention study/ 219248 exp replication study/ 98549 exp theoretical study/ 142630950 exp Feasibility Studies/ 10207151 exp trend study/ 1161552 exp correlational study/ 1187153 exp case-control studies/ 80839354 exp confidence interval/ 12491355 exp regression analysis/ 58996756 exp proportional hazards model/ 9935557 exp multivariate analysis/ 35262058 ((evidence adj based) or (outcome* adj (research or assessment*)) or (meta adj analys*) or (systematic* adj3 review*) or
guideline* or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo* or nocebo* or random* or control* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or compar* or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") adj3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "population study" or "population survey" or "population analysis" or "population research" or "concurrent study" or "concurrent survey" or "concurrent analysis" or "incidence study" or "incidence survey" or "incidence analysis" or (("follow-up" or followup) adj (stud* or survey or analysis)) or ((observation or observational) adj (study or survey or analysis)) or "case study" or "case series" or "clinical series" or "case studies" or "clinical study" or "clinical trial" or "evaluation study" or "evaluation survey" or "evaluation analysis" or "quantitative study" or "quantitative analys*" or "numerical study" or "validation study" or "validation survey" or "validation analysis" or "experimental study" or "experimental analysis" or "quasi experimental study" or "quasi experimental analysis" or "quasiexperimental study" or "quasiexperimental analysis" or "field study" or "field survey" or "field analysis" or "in vivo study" or "in vivo analysis" or "panel study" or "panel survey" or "panel
22826290
5
analysis" or "pilot study" or "pilot survey" or "pilot analysis" or "pilot project" or ((prevention or preventive) adj3 (trial or study or analysis or survey)) or "replication study" or "replication analysis " or "replication trial" or "theoretical study" or "theoretical analysis " or "feasibility study" or "feasibility analysis" or "trend study" or "trend survey" or "trend analysis" or ((correlation* adj2 study) or (correlation* adj2 analys*)) or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multi-center study" or study or trial or pilot or "odds ratio" or "confidence interval" or "regression analysis" or "least square" or "least squares" or (hazard* adj (model or analys* or regression)) or "Cox model" or "Cox multivariate analyses" or "Cox multivariate analysis" or "Cox regression" or "Cox survival analyses" or "Cox survival analysis" or "Cox survival model" or "change analysis" or ((study or trial or random* or control*) and compar*)).mp,pt.
59 or/13-58 2372570660 12 and 59 169761 from 12 keep 902-2274 1373
62
limit 61 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or controlled clinical trial or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or comparative study or controlled clinical trial or evaluation studies or guideline or practice guideline or meta analysis or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or systematic reviews or validation studies) [Limit not valid in Embase,CCTR,CDSR; records were retained]
365
63 60 or 62 1697
64
limit 63 to (book or book series or editorial or erratum or letter or note or addresses or autobiography or bibliography or biography or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were retained]
50
65 63 not 64 164766 from 12 keep 2275-2369 9567 65 or 66 1664
68limit 67 to ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)") [Limit not valid in Embase,CCTR,CDSR; records were retained]
1418
69 limit 68 to (adult <18 to 64 years> or aged <65+ years>) [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) In- 1167
6
Process,CCTR,CDSR; records were retained]70 67 and (adult or adults or "middle age" or "middle aged").mp. 110171 69 or 70 120972 limit 71 to yr="1970 -Current" 120973 remove duplicates from 72 837
Table I: Characteristics of the included studies:Study ID Patients characteristic Co Intervention Cohort selection Lost to
follow upCante, 19981 End stage renal disease (ESRD) NA None reported or
unclear samplingNot reported
Dhingra, 20012 ESRD NA Our experience Not
7
(All patients) reported
Keuter, 20083 Patients with radiocephalic or brachiocephalic arteriovenous fistulas failure, on aspirin unless already on anticoagulation
NA Our experience (All patients)
Not reported
D’Ayala, 20084 ESRD Systemic heparin 57 patients a consecutive sample
2.609
Fassiadis, 20075 ESRD NA a consecutive sample
Not reported
Elwakeel, 20076 ESRD with no suitable superficial vein NA Our experience (All patients)
Not reported
Keeling, 2007 7 ESRD NA a consecutive sample
7.965
Nikeghbalian, 20068
ESRD NA Our experience (All patients)
Not reported
MAYA, 20059 ESRD NA Our experience (All patients)
Not reported
Rooijens, 2005 10 ESRD NA a consecutive sample
3.846
Madden, 2005 11 ESRD NA Our experience (All patients)
Not reported
Chen, 200512 ESRD Outflow Venovenostomy Our experience 0
8
(All patients)
Akoh, 200513 ESRD NA Our experience (All patients)
0.45
Brueck, 2004 14 ESRD NA a consecutive sample
Not reported
Di Iorio, 200415 ESRD NA Our experience (All patients)
Not reported
Rao, 2004 16 ESRD NA Our experience (All patients)
27
KAO, 200417 ESRD NA Our experience (All patients)
Not reported
Flarup, 200318 ESRD NA Our experience (All patients)
Not reported
Segal, 200319 ESRD NA Our experience (All patients)
Not reported
Gallieni, 2002 20 ESRD NA Our experience (All patients)
Not reported
Hingorani, 2001 21 ESRD NA Our experience (All patients)
Not reported
Berman, 200122 ESRD NA Our experience (All patients)
Not reported
vogel, 200023 ESRD NA a consecutive 0
9
sample
Miller, 1999 24 ESRD NA Our experience (All patients)
2.58621
khadra, 1997 25 ESRD NA Our experience (All patients)
Not reported
PALDER, 1985 26 ESRD NA Our experience (All patients)
Not reported
Rabbani, 2006 27 ESRD NA Our experience (All patients)
Not reported
SENKAYA, 200628
ESRD NA Our experience (All patients)
Not reported
Hood, 199429 ESRD Percutaneous balloon angioplasty Our experience (All patients)
Not reported
BRUNORI, 200030 ESRD NA Our experience (All patients)
Not reported
Choi, 200331 ESRD NA a consecutive sample
0
Dixon, 200232 ESRD NA Our experience (All patients)
Not reported
Matsuura, 199833 ESRD NA a consecutive sample
Not reported
Silva, 199834 ESRD Doppler pressures and duplex Our experience Not
10
ultrasound with mapping (All patients) reported
Staramos, 200035 ESRD NA a consecutive sample
1.75
Kokkosis, 2013 36 Cardiovascular comorbidity NA Our experience (All patients)
0
Goldfarb-Rumyantze, 201337
Renal transplantation NA None reported or unclear sampling
Not reported
Al-Benna, 201338 ESRD NA Our experience (All patients)
Not reported
Sahin, 2011 39 ESRD Duplex Doppler Our experience (All patients)
0
Chiulli, 201140 ESRD NA Our experience (All patients)
Not reported
Bonforte, 2010 41 ESRD NA Our experience (All patients)
Not reported
Ferring, 201042 ESRD NA Our experience (All patients)
0
Kybartiene, 201043 ESRD Antibiotics Our experience (All patients)
2
Stuard, 201044 ESRD Clopidogrel or aspirin with or without heparin
Our experience (All patients)
Not reported
Garcia Cortes, ESRD NA None reported or Not
11
200545 unclear sampling reported
Jimenez-Almonacid, 2004 46
ESRD NA a consecutive sample
Not reported
Hernandez-Jaras, 200447
ESRD NA Our experience (All patients)
Not reported
Rodriguez, 200148 ESRD NA Our experience (All patients)
Not reported
Branger, 201149 ESRD NA Our experience (All patients)
Not reported
Kennealey, 201150 ESRD NA Our experience (All patients)
Not reported
Diehm, 201051 ESRD NA Our experience (All patients)
Not reported
Wasse, 200852 ESRD NA Our experience (All patients)
Not reported
Ko, 200953 Patients without suitable superficial veins NA Our experience (All patients)
Not reported
Slayden, 200854 ESRD converting arteriovenous grafts to Secondary arteriovenous fistulas
a consecutive sample
Not reported
EKBAL, 200855 ESRD NA Our experience (All patients)
Not reported
12
Tsoulfas, 200856 ESRD NA Our experience (All patients)
Not reported
Long, 200857 ESRD with peri anastomotic stenosis Surgery or angioplasty Our experience (All patients)
0
Qasaimeh, 200858 ESRD NA Our experience (All patients)
0
Bronder, 200859 ESRD Fistula Elevation Procedure Consecutive Not reported
Torina, 200860 ESRD NA Our experience (All patients)
Not reported
Shahnawaz, 201361 ESRD NA Our experience (All patients)
Not reported
Morale, 201162 ESRD NA Our experience (All patients)
10
Lee, 201163 ESRD Preoperative ultra sound None reported or unclear sampling
Not reported
Moussavi, 200764 ESRD NA a consecutive sample
Not reported
Savader, 200065 ESRD NA Our experience (All patients)
Not reported
Hurlbert, 199866 ESRD NA a consecutive sample
0
13
McLaughlin, 199767
ESRD Antibiotics 1 g IV vancomycin Our experience (All patients)
Not reported
Ozlem, 199668 ESRD NA Our experience (All patients)
Not reported
Tedoriya, 199569 ESRD NA Our experience (All patients)
Not reported
Beigi, 200970 ESRD NA a consecutive sample
Not reported
Gormus, 200371 ESRD NA None reported or unclear sampling
Not reported
Polo, 200472 ESRD NA a consecutive sample
0
Ascher, 200173 ESRD Preoperative ultra sound Our experience (All patients)
Not reported
Astor, 200574 ESRD NA Our experience (All patients)
Not reported
Coburn, 199475 ESRD NA Our experience (All patients)
1.235
Haimov, 198076 ESRD NA Our experience (All patients)
Not reported
Hazinedaroglu, 200477
ESRD Preoperative venography, prophylactic dose of 1.5 g
Our experience (All patients)
Not reported
14
ampicillin + sulbactam IV
Kherlakian, 198678 ESRD NA Our experience (All patients)
Not reported
Kim, 199579 ESRD NA Our experience (All patients)
Not reported
Oliver, 200180 ESRD NA None reported or unclear sampling
3.77
Perera, 200481 ESRD NA a consecutive sample
13.39713
Polkinghorne, 200482
ESRD in Australia and New Zealand NA Our experience (All patients)
0
Ridao-Cano, 200283
ESRD Preoperative venography Our experience (All patients)
4.931
Sparks, 199784 ESRD NA Our experience (All patients)
Not reported
Tordoir, 198385 ESRD NA Our experience (All patients)
Not reported
Shemesh, 200886 Recurrent cephalic arch stenosis >50% within 3 months of successful balloon angioplasty
Endovascular intervention + preoperative ultra sound
a consecutive sample
0
Flu, 200887 ESRD NA a consecutive sample
0
15
Kakkos, 200888 ESRD NA a consecutive sample
0.5
Wu, 200889 ESRD with access dysfunction Balloon angioplasty for dialysis access dysfunction or thrombosis
Our experience (All patients)
Not reported
Kakkos, 200890 ESRD NA a consecutive sample
Not reported
Jean -Baptiste, 200891
ESRD Preoperative ultra sound Our experience (All patients)
0
Schild, 200792 ESRD HIV without sufficient veins for an autologous fistula
NA a consecutive sample
Not reported
Moossavi, 200793 ESRD Surgeon experience, interventional radiologists, intervention within 48 hours of thrombosis
a consecutive sample
Not reported
Woo, 200794 ESRD Preoperative ultra sound Our experience (All patients)
Not reported
Kayacioglu, 200795 ESRD, with diabetes NA None reported or unclear sampling
Not reported
Lee, 200796 ESRD Preoperative mapping, Surgeon experience
Our experience (All patients)
Not reported
Shemesh, 200797 ESRD Single dose of Cefamezine a consecutive sample
1.515
Basaran, 200798 ESRD Anti-platelets aspirin 300 mg/day None reported or Not
16
unclear sampling reported
Korten, 200799 ESRD Preoperative ultra sound a consecutive sample
Not reported
Yilmaz, 2007100 ESRD, 1-4 previous access attempts NA a consecutive sample
7.1
Mitchell, 2007101 ERSD HIV (+) vs. (-) NA Our experience (All patients)
Not reported
Inrig, 2006102 ESRD, Patients with Staphylococcus aureus Bacteremia
Surgical and percutaneous treatment of thrombosis, preoperative ultra sound
Our experience (All patients)
0
Karakayali, 2006103
ESRD NA Our experience (All patients)
Not reported
El Sayed, 2005104 ESRD Preoperative ultra sound Our experience (All patients)
14.1
Fitzgerald, 2005105 ESRD Preoperative ultra sound, preoperative venography
Our experience (All patients)
Not reported
Modarai, 2005106 ESRD, Radiocephalic, brachiocephalic and brachiobasilic fistulas not possible
NA Our experience (All patients)
Not reported
Kizilisik, 2004107 ESRD NA Our experience (All patients)
Not reported
Ko, 2004108 ESRD NA a consecutive sample
Not reported
17
Fitzgerald, 2004109 ESRD NA Our experience (All patients)
Not reported
Mazzoni, 2003110 ESRD Preoperative ultra sound Our experience (All patients)
0
Senkaya, 2003111 ESRD 300mg aspirin None reported or unclear sampling
0
Xue, 2003112 ESRD NA a consecutive sample
Not reported
Shenoy, 2003113 ESRD NA Our experience (All patients)
Not reported
Bruns, 2003114 ESRD NA Our experience (All patients)
8.2
Wiese, 2003115 ESRD, absence of sufficient native vessels to create an AV fistula
Color Doppler ultrasound Our experience (All patients)
6.7
Baldrati, 2003116 ESRD NA a consecutive sample
Not reported
Hossny, 2003117 ESRD NA Our experience (All patients)
2.857
Dalman, 2002118 ESRD NA a consecutive sample
Not reported
Sorom, 2002119 ESRD Preoperative ultra sound, 1 aspirin daily
a consecutive sample
Not reported
18
Ascher, 2001120 ESRD NA Our experience (All patients)
Not reported
Wolowczyk, 2000121
ESRD NA Our experience (All patients)
35
Taylor, 1996122 ESRD First generation cephalosporin or vancomycin given at dialysis
a consecutive sample
Not reported
Helling, 1992123 ESRD NA a consecutive sample
Not reported
Nannery, 1991124 ESRD, HIV, IV drug abusers NA Our experience (All patients)
0
Donnelly, 1988125 ESRD Heparin Our experience (All patients)
Not reported
Rizzuti, 1988126 ESRD Antibiotics Our experience (All patients)
Not reported
Elwakeel, 2013127 ESRD patients with no suitable vein to perform autogenous arteriovenous fistulas
Preoperative ultra sound Our experience (All patients)
Not reported
Fredette, 2013128 ESRD in Octogenarian (>80 years old) Vascular mapping Our experience (All patients)
Not reported
Scarritt, 2014129 ESRD not appropriate candidates for a primary fistula
NA a consecutive sample
Not reported
Hruby, 2013130 ESRD Duplex Doppler Ultrasound Our experience Not
19
(All patients) reported
Kanko, 2012131 ESRD NA a consecutive sample
Not reported
Gage, 2012132 ESRD NA Our experience (All patients)
Not reported
Basel, 2011133 ESRD Duplex scanning a consecutive sample
Not reported
Walker, 2012134 ESRD Duplex scanning Our experience (All patients)
Not reported
Huddam, 2012135 ESRD NA None reported or unclear sampling
Not reported
Woo, 2012136 ESRD NA Our experience (All patients)
Not reported
Lukowsky, 2012137 ESRD NA Our experience (All patients)
Not reported
Solid, 2012138 ESRD NA Our experience (All patients)
Not reported
Matsumoto, 2012139
ESRD Preoperative ultra sound Our experience (All patients)
Not reported
Desilva, 2012140 ESRD NA Our experience (All patients)
Not reported
Vahedian, 2012141 ESRD Preoperative ultra sound Our experience 0
20
(All patients)
Jackson, 2011142 ESRD with Angiotensin receptor blocker VS. No Angiotensin receptor blocker
NA None reported or unclear sampling
Not reported
Chan, 2011143 ESRD NA Our experience (All patients)
Not reported
Conte, 2011144 ESRD, Cardiovascular comorbidity Vascugel or placebo prior to surgery
None reported or unclear sampling
6.45
Powell, 2010145 ESRD Preoperative ultra sound, preoperative venography
None reported or unclear sampling
Not reported
Karakayali, 2007146
ESRD Preoperative ultra sound, preoperative venography
a consecutive sample
Not reported
Hamida, 2005147 ESRD NA None reported or unclear sampling
Not reported
Cetinkaya, 2003148 ESRD NA None reported or unclear sampling
Not reported
Gorski, 2002149 HIV NA a consecutive sample
Not reported
Ravani, 2002150 ESRD Preoperative ultra sound a consecutive sample
Not reported
BACCHINI, 2001151
ESRD, impairment of native AVF NA None reported or unclear sampling
Not reported
Friedman, 2000152 ESRD NA None reported or 5.83
21
unclear sampling
Leapman, 1995153 ESRD NA None reported or unclear sampling
0
Cohen, 1994154 ESRD who underwent thrombolysis for thrombosed hemodialysis
Percutaneous transluminal balloon angioplasty
Our experience (All patients)
13
Viron, 1987155 ESRD NA None reported or unclear sampling
Not reported
Weale, 2008156 ESRD Preoperative ultra sound Our experience (All patients)
14.29
Gargiulo, 1999157 ESRD Antibiotics, preoperative ultra sound
Our experience (All patients)
17.65
Mortazavi, 2011158 ESRD NA Our experience (All patients)
0
Gibson, 2001159 ESRD NA a consecutive sample
Not reported
Taylor, 1993160 ESRD NA None reported or unclear sampling
Not reported
Morosetti, 2011161 ESRD Ceftazidime (1 g) was administered as a single-dose therapy
a consecutive sample
Not reported
Chen, 2010162 ESRD NA None reported or unclear sampling
Not reported
22
Gonzalez, 2010163 ESRD NA a consecutive sample
Not reported
Dember, 2008164 ESRD Preoperative ultra sound a consecutive sample
3.763
Louridas 165, 1984 ESRD NA Our experience (All patients)
Not reported
Foley, 2009166 ESRD NA a consecutive sample
Not reported
Salman, 2009167 ESRD Preoperative venography Our experience (All patients)
Not reported
Bradbury, 2009168 ESRD NA a consecutive sample
Not reported
Pisoni, 2009169 ESRD NA a consecutive sample
Not reported
Bhomi, 2008170 ESRD 5000 IU of intravenous heparin during surgery vs no heparin
a consecutive sample
Not reported
Grubbs, 2013171 ESRD NA Our experience (All patients)
Not reported
Jemcov, 2013172 ESRD Preoperative ultra sound a consecutive sample
Not reported
Alhassan, 2013173 ESRD in Nigerians NA a consecutive sample
2.87
23
Ilhan, 2013174 ESRD Preoperative ultra sound Our experience (All patients)
Not reported
Manson, 2012175 ESRD Opti-Flow Vascular Anastomosis Device
None reported or unclear sampling
Not reported
Wongkonkitsin, 2014176
ESRD in Thai Preoperative ultra sound Our experience (All patients)
Not reported
Watorek, 2014177 ESRD in Octogenarian (>80 years old) NA Our experience (All patients)
Not reported
Wetzig, 1985178 ESRD Preoperative venography, bilateral upper extremity central venograms
a consecutive sample
0
Hart, 2014179 ESRD NA Our experience (All patients)
0
Persic, 2013180 ESRD Preoperative ultra sound Our experience (All patients)
2.5
Prischl, 1995181 ESRD Preoperative ultra sound a consecutive sample
Not reported
Kaufman, 1997182 ESRD Preoperative ultra sound a consecutive sample
1.7
Lok, 2005183 ESRD NA a consecutive sample
Not reported
Vaux, 2013184 ESRD NA Our experience (All patients)
0
24
Bender, 1995185 ESRD NA Our experience (All patients)
Not reported
Yasuhara, 1997186 ESRD NA Our experience (All patients)
Not reported
Wang, 1996187 ESRD Antibiotics Our experience (All patients)
Not reported
kalman, 1999188 ESRD NA a consecutive sample
Not reported
ELCHEROTH, 1994189
ESRD NA Our experience (All patients)
Not reported
Simoni, 1994190 ESRD NA Our experience (All patients)
Not reported
Rubens, 1993191 ESRD NA Our experience (All patients)
Not reported
BURT, 2001192 ESRD NA a consecutive sample
Not reported
Golledge, 1999193 ESRD NA our experience (All patients)
not reported
Lemson, 2000194 ESRD Antibiotics a consecutive sample
not reported
Curi, 1999195 ESRD HIV (+) vs. (-) NA our experience 1.92%
Munda, 1983196 ESRD NA our experience not
25
(all patients) reported
Silva, 1997197 ESRD Preoperative ultra sound our experience (all patients)
0
Hakaim, 1997198 ESRD NA our experience (all patients)
not reported
Bone, 1980199 ESRD 1 g of cephalothin a consecutive sample
not reported
Hibberd, 1991200 ESRD primary vascular access was not possible
All had pre-operative upper limb venography
a consecutive sample
not reported
Table II: Outcomes (rate, 95% confidence interval) per vascular access type:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Arteriovenous fistula 0.548 (0.522- 0.576) at 104 weeks*
0.627 (0.586- 0.670) at 104 weeks
0.787 (0.743- 0.834) at 65 weeks
0.153 (0.125- 0.187) at 104 weeks
0.827 (0.773- 0.885) at 26 weeks
0.021 (0.010 - 0.043) at 104 weeks
Arteriovenous graft 0.395 (0.353- 0.442) at 104 weeks
0.599 (0.548- 0.653) at 104 weeks
0.527 (0.422- 0.658) at 52 weeks
0.170 (0.135- 0.215) at 71.5 weeks
0.960 (0.858- 1.074) at 39 weeks
0.127 (0.097- 0.166) at 104 weeks
26
Catheter 0.499 (0.408-0.609) at 86 weeks
0.429 (0.267-0.687) at 39 weeks
0.763 (0.499-1.165) at 26 weeks
0.256 (0.203- 0.323) at 112 weeks
0.164 (0.078-0.344) at 59 weeks
HeRO 0.429 (0.361-0.510) at 104 weeks
0.704 (0.391-1.270) at 78 weeks
0.178 (0.128-0.248) at 122.8 weeks
0.038 (0.016-0.086) at 122.8 weeks
*The follow up is reported as median for all outcomes.
Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:
III.1: Arteriovenous fistula (AVF), unspecified location:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.556 (0.512-0.605) at 91 weeks
0.652 (0.590-0.720) at 104 weeks
0.687 (0.580-0.812) at 52 weeks
0.152 (0.117-0.196) at 69 weeks
0.813 (0.676-0.978) at 19.5 weeks
0.023 (0.007-0.074) at 93 weeks
Age <50. 0 at 56 weeks 0 at 56 weeks
27
Age <65. 0.684 (0.642-0.729) at 130 weeks
0.800 (0.760-0.841) at 156 weeks
Age >40. 0.818 (0.700-0.956) at 52 weeks
Age >65. 0.686 (0.620-0.759) at 104 weeks
0.818 (0.745-0.898) at 130 weeks
0.249 (0.239-0.260) at 52 weeks
Age >70. 0.441 (0.332-0.586) at 156 weeks
0.441 (0.332-0.586) at 156 weeks
0.333 (0.146-0.761) at 52 weeks
0.133 (0.027-0.659) at 130 weeks
Age >75. 0.588 (0.374- 0.926) at 86 weeks
0.176 (0.052-0.597) at 130 weeks
Age >80. 0.294 (0.166-0.522) at 216 weeks
0.294 (0.166-0.522) at 156 weeks
Age 50-60.* 0.341 (0.215-0.542) at 86 weeks
0.366 (0.236-0.567) at 130 weeks
0.118 (0.041-0.339) at 156 weeks
Currently dialyzing through a catheter.
0.554 (0.446-0.688) at 104 weeks
0.246 (0.236-0.256) at 52 weeks
Diabetes Mellitus. 0.524 (0.422-0.651) at 44.5 weeks
0.598 (0.262-1.365) at 454 weeks
0.235 (0.198-0.278) at 52 weeks
Women. 0.062 (0.005-0.864) at 104 weeks
28
History of previous access failure.
0.578 (0.503-0.663) at 84.5 weeks
0.901 (0.850-0.956) at 104 weeks
Inflow artery minimum diameter 2-2.5 mm.
0.873 (0.810-0.940) at 26 weeks
0.958 (0.917-1.000) at 4 weeks
Men. 0 at 56 weeks 0 at 56 weeks
No Diabetes Mellitus. 0.366 (0.280-0.480) at 65 weeks
0.884 (0.804-0.972) at 936 weeks
0.207 (0.182-0.236) at 52 weeks
Non dominant side. 0.486 (0.324-0.729) at 26 weeks
0.367 (0.310-0.434) at 572 weeks
Pre-dialysis: anticipated start 1 year.
0.769 (0.696-0.850) at 104 weeks
Upper extremity minimum outflow vein diameter >3 mm.
0.900 (0.671-1.207) at 6 weeks
Upper extremity minimum outflow vein diameter 2.5-3 mm.
0.491 (0.426-0.565) at 104 weeks
Upper extremity minimum outflow vein diameter 2-2.5 mm.
0.873 (0.810-0.940) at 26 weeks
0.958 (0.917-1.000) at 4 weeks
* Results are mutually exclusive to this subgroup.
III.2: Upper arm AVF:Group Primary Secondary Assisted Mortality Maturation Infection
29
Patency Patency PatencyOverall. 0.535 (0.429-
0.668) at 104 weeks
0.671 (0.545-0.826) at 104 weeks
0.698 (0.589-0.792) at 104 weeks
0.047 (0.001-1.646) at 104 weeks
0.972 (0.937-1.009) at 82 weeks
0 at 82 weeks
Age >70. 0.552 (0.384-0.792) at 104 weeks
III.3: Brachial- Basilic fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.582 (0.511-0.664) at 104 weeks
0.722 (0.645-0.809) at 91 weeks
0.857 (0.736-0.998) at 65 weeks
0.104 (0.054-0.201) at 104 weeks
0.780 (0.685-0.888) at 34.15 weeks
0.019 (0.004-0.092) at 115 weeks
Age <65. 0.357 (0.158-0.805) at 104 weeks
Age >65. 0.364 (0.144-0.915) at 52 weeks
Black. 0.600 (0.456-0.790) at 115 weeks
Diabetes Mellitus. 0.947 (0.862-1.041) at 52 weeks
0.84 (0.720-0.985) at 52 weeks
Women. 0.658 (0.422-1.025) at 109.5 weeks
30
Men. 0.933 (0.827-1.053) at 104 weeks
Non dominant side. 0.900 (0.671-1.207 ) at 43 weeks
0 at 43 weeks 0 at 43 weeks
Upper extremity minimum outflow vein diameter >3 mm.
0.900 (0.671-1.207) at 43 weeks
0 at 43 weeks 0 at 43 weeks
Upper extremity minimum outflow vein diameter 2.5-3 mm.
0.480(0.372-0.620) at 260 weeks
0.648 (0.574-0.732) at 260 weeks
0.042 (0.016-0.111) at 4 weeks
0.025 (0.007-0.093) at 121 weeks
III.4: Brachial-brachial fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.586 (0.457- 0.751) at 92 weeks
0.455 (0.213-0.972) at 52 weeks
0.143 (0.03-0.363) at 125 weeks
0.213 (0.026-1.719) at 78 weeks
III.5: Brachial-Cephalic fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.526 (0.458-0.604) at 130 weeks
0.573 (0.435-0.755) at 104.5 weeks
0.966 (0.950-0.983) at 260 weeks
0.325 (0.175-0.603) at 93.4 weeks
0.863 (0.588- 1.268) at 6 weeks
0.001 (0.000-0.685) at 130 weeks
Age <65. 0.475 (0.245-0.920) at 156 weeks
0.339 (0.262-0.437) at 105 weeks
31
Age >65. 0.452 (0.357-0.572) at 156 weeks
Age >80. 0.592 (0.329-1.065) at 156 weeks
0.429 (0.303-0.607) at 104 weeks
Age 60-70. 0.820 (0.753-0.894) at 208 weeks
Age 65-80. 0.543 (0.263-1.118) at 156 weeks
0.388 (0.307-0.491) at 105 weeks
BMI < 18. 0.686 (0.536-0.878) at 208 weeks
BMI > 25. 0.893 (0.845-0.943) at 208 weeks
BMI 18-25. 0.737 (0.682-0.796) at 208 weeks
Women. 0.772 (0.711-0.838) at 208 weeks
History of previous access failure.
0.802 (0.727-0.885) at 537 weeks
Men. 0.804 (0.756-0.854) at 208 weeks
32
Upper extremity minimum outflow vein diameter 2.5-3 mm.
0.394 (0.290-0.536) at 260 weeks
0.465 (0.357-0.606) at 260 weeks
0 at 4 weeks 0 at 121 weeks
III.6: Forearm AVF:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.460 (0.293-0.721) at 156 weeks
0.905 (0.869-0.941) at 260 weeks
0.431 (0.293-0.578) at 260 weeks
0 at 104 weeks
Diabetes Mellitus. 0.325 (0.249-0.423) at 208 weeks
0.823 (0.736-0.919) at 260 weeks
0.431 (0.293-0.578) at 260 weeks
No Diabetes Mellitus. 0.294 (0.121-0.714) at 260 weeks
0.922 (0.883-0.962) at 260 weeks
III.7: Radiocephalic fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.554 (0.505-0.608) at 104 weeks
0.536 (0.423-0.679) at 104 weeks
0.858 (0.754-0.976) at 52 weeks
0.173 (0.114-0.263) at 104 weeks
0.781 (0.647-0.943)4 at 45.5 weeks
0.021 (0.007-0.064) at 156 weeks
Age <50. 0.511 (0.375-0.696) at 156 weeks
Age <60. 0.538 (0.363-0.799) at 104 weeks
0.654 (0.478-0.893) at 104 weeks
0.269 (0.132-0.547) at 104 weeks
0.923 (0.803-1.062) at 104 weeks
33
Age <65. 0.319 (0.239-0.426) at 130 weeks
0.280 (0.216-0.362) at 104 weeks
Age <70. 0.560 (0.478-0.655) at 260 weeks
Age >60. 0.593 (0.419-0.838) at 104 weeks
0.630 (0.456-0.868) at 104 weeks
0.185 (0.075-0.455) at 104 weeks
0.741 (0.576-0.953) at 104 weeks
Age >65. 0.413 (0.319-0.534) at 156 weeks
0.047 (0.009-0.245) at 104 weeks
Age >70. 0.337 (0.245-0.462) at 208 weeks
Age >80. 0.383 (0.259-0.566) at 104 weeks
0.404 (0.278-0.588) at 104 weeks
Age 50-59. 0.364 (0.196-0.675) at 156 weeks
Age 60-69. 0.364 (0.222-0.596) at 156 weeks
Age 65-79. 0.359 (0.288-0.448) at 104 weeks
0.373 (0.301-0.462) at 104 weeks
Current Smoking 0.591 (0.400-0.873) at 78 weeks
Currently dialyzing 0.447 (0.374-
34
through a catheter. 0.535) at 260 weeks
Diabetes Mellitus. 0.373 (0.278-0.499) at 156 weeks
0.500 (0.337-0.741) at 104 weeks
Women. 0.200 (0.145-0.277) at 156 weeks
0.441 (0.292-0.667) at 104 weeks
0.857 (0.761-0.966) at 8 weeks
History of previous access failure.
0.680 (0.606-0.764) at 520 weeks
Inflow artery minimum diameter 2-2.5 mm.
0.745 (0.620-0.894) at 52 weeks
0.924 (0.854-1.000) at 8 weeks
Inflow artery minimum diameter >2.5 mm.
0.524 (0.383-0.716) at 52 weeks
Inflow artery minimum diameter 1.5-2 mm.
0.480 (0.352-0.655) at 52 weeks
0.857 (0.761-0.966) at 8 weeks
Left side. 0.474 (0.380-0.591) at 52 weeks
Men. 0.550 (0.437-0.693) at 156 weeks
0.730 (0.629-0.847) at 105 weeks
0.924 (0.854-1.000) at 8 weeks
Never Smoke. 0.825 (0.729-0.935) at 78 weeks
35
No Diabetes Mellitus. 0.533 (0.412-0.689) at 182 weeks
0.701 (0.600-0.819) at 104 weeks
Non dominant side. 0.452 (0.387-0.528) at 260 weeks
0.351 (0.290-0.425)
0.782 (0.681-0.897) at 42 weeks
Pre-dialysis: Anticipated start 6 months to 1 year.
0.532 (0.398-0.710) at 260 weeks
Pre-dialysis: Anticipated start in 1 year.
0.532 (0.398-0.710) at 260 weeks
Pre-dialysis: Anticipated start less than 6 months.
0.532 (0.398-0.710) at 260 weeks
Upper extremity minimum outflow vein diameter <1 mm.
0.650 (0.451-0.936) at 78 weeks
Upper extremity minimum outflow vein diameter 2-2.5 mm.
0.902 (0.84-0.967) at 8 weeks
III.8: Forearm basilic fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.377 (0.184-0.774) at 104 weeks
0.627 (0.436-0.902) at 80.6 weeks
0.288 (0.221-0.363) at 208 weeks
0.051 (0.019-0.134) at 104 weeks
0 at 104 weeks
36
III.9: Lower extremity fistula:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.460 (0.189-1.122) at 52 weeks
0.727 (0.469-1.129) at 39 weeks
0 (0.000-6.500) at 40.6 weeks
History of previous access failure.
0 at 52 weeks
No Diabetes Mellitus. 0.867 (0.674-1.114) at 52 weeks
0.267 (0.100-0.709) at 29.2 weeks
III.10: Arteriovenous graft (AVG), unspecified location:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.373 (0.324-0.430) at 104 weeks
0.641 (0.590-0.696) at 104 weeks
0.459 (0.349-0.602) at 52 weeks
0.175 (0.129-0.237) at 52 weeks
0.123 (0.079-0.190) at 104 weeks
Age <50. 0.118 (0.024-0.588) at 43 weeks
0.200 (0.051-0.782) at 43 weeks
Age <65. 0.401 (0.325-0.496) at 130 weeks
0.748 (0.676-0.828) at 156 weeks
Age >40. 0.536 (0.366-0.784) at 52 weeks
37
Age >65. 0.372 (0.292-0.474) at 130 weeks
0.718 (0.635-0.813) at 156 weeks
0.281 (0.275-0.288) at 52 weeks
Diabetes Mellitus. 0.400 (0.099-1.609) at 312 weeks
Women. 0.500 (0.342-0.731) at 104 weeks
0.750 (0.600-0.938) at 104 weeks
0.500 (0.056-4.430) at 43 weeks
Men. 0.467 (0.251-0.867) at 104 weeks
0.467 (0.251-0.867) at 104 weeks
0.118 (0.024-0.588) at 43 weeks
0.118 (0.024-0.588) at 43 weeks
No Diabetes Mellitus. 0.267 (0.100-0.709) at 312 weeks
Non dominant side. 0.774 (0.625-0.959) at 13 weeks
Upper extremity minimum outflow vein diameter 2.5-3 mm.
0.300 (0.225-0.400) at 104 weeks
III.11: Upper arm graft:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.441 (0.354-0.550) at 88.5 weeks
0.391 (0.229-0.666) at 104 weeks
0.492 (0.213-1.133) at 52 weeks
0.121 (0.055-0.262) at 78 weeks
0.886 (0.733-0.968) at 13 weeks
0.116 (0.057-0.234) at 112.5 weeks
38
Age <71. 0.586 (0.475-0.722) at 156 weeks
0.886 (0.807-0.973) at 156 weeks
0.843 (0.754-0.942) at 156 weeks
0.100 (0.046-0.218) at 156 weeks
0.129 (0.066-0.251) at 156 weeks
Age 70-80. 0.641 (0.526-0.780) at 104 weeks
History of previous access failure.
0.429 (0.246-0.745) at 13 weeks
Never Smoke. 0.327 (0.218-0.492) at 104 weeks
No Diabetes Mellitus. 0.450 (0.255-0.794) at 130 weeks
0.886 (0.807-0.973) at 156 weeks
0.843 (0.754-0.942) at 156 weeks
0.100 (0.046-0.218) at 156 weeks
0.129 (0.066-0.251) at 156 weeks
III.12: Forearm graft:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.332 (0.247-0.447) at 104 weeks
0.463 (0.203-1.053) at 86 weeks
0.667 (0.543-0.820) at 86 weeks
0.222 (0.135-0.363) at 58.5 weeks
1.000 (0.970-1.031) at 65 weeks
0.114 (0.075-0.174) at 145 weeks
Diabetes Mellitus. 0.786 (0.564-1.094) at 52 weeks
Men. 0.650 (0.451-0.936) at 104 weeks
0.100 (0.020-0.507) at 117 weeks
39
III.13: Axillary-Axillary graft:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.513 (0.283-0.931) at 104 weeks
0.611 (0.333-1.118) at 91 weeks
0.142 (0.076-0.266) at 130 weeks
0.161 (0.089-0.290) at 130 weeks
Age >50. 0.519 (0.347-0.775) at 78 weeks
0.815 (0.662-1.002) at 78 weeks
0.185 (0.075-0.455) at 208 weeks
0.111 (0.032-0.391) at 208 weeks
III.14: Lower extremity graft:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.583 (0.441-0.772) at 104 weeks
0.182 (0.038-0.866) at 104 weeks
0.333 (0.191-0.502) at 572 weeks
0.202 (0.158-0.258) at 52 weeks
Currently dialyzing through a catheter.
0.467 (0.333-0.654) at 104 weeks
0.178 (0.089-0.356) at 572 weeks
History of previous access failure.
0.467 (0.333-0.654) at 104 weeks
0.178 (0.089-0.356) at 572 weeks
No Diabetes Mellitus. 0.353 (0.169-0.735) at 52 weeks
0.353 (0.169-0.735) at 52 weeks
III.15: Tunneled cuffed catheter, unspecified location:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
40
Overall. 0.452 (0.296-0.692) at 156 weeks
0.429 (0.245-0.628) at 39 weeks
0.357 (0.243-0.525) at 52 weeks
0.167 (0.083-0.285) at 29 weeks
Age >67. 0.415 (0.410-0.420) at 52 weeks
Age >80. 0.600 (0.446-0.807) at 156 weeks
0.600 (0.446-0.807) at 156 weeks
Age 50-60. 0.429 (0.246-0.745) at 156 weeks
0.429 (0.246-0.745) at 156 weeks
History of previous access failure.
0.167 (0.083-0.285) at 29 weeks
III.16: Tunneled cuffed IJ/subclavian PermCath:Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.511 (0.411-0.637) at 82 weeks
0.763 (0.499-1.165) at 26 weeks
0.211 (0.130-0.343) at 116.5 weeks
0.163 (0.075-0.356) at 83.5 weeks
Age >70. 0.073 (0.038-0.140) at 78 weeks
0.102 (0.060-0.174) at 78 weeks
Age >75. 0.467(0.251-0.867) at 86 weeks
0.600 (0.373-0.966) at 130 weeks
41
III.17: Hybrid graft and catheter (HeRO):Group Primary
PatencySecondary Patency
Assisted Patency
Mortality Maturation Infection
Overall. 0.429 (0.361-0.510) at 104 weeks
0.704 (0.391-1.270) at 78 weeks
0.178 (0.128-0.248) at 122.8 weeks
0.038 (0.016-0.086) at 122.8 weeks
History of previous access failure.
0.091 (0.018-0.464) at 52 weeks
0.227 (0.094-0.547) at 52 weeks
HTN 0.091 (0.002-0.413) at 52 weeks
0.455 (0.167-0.766) at 52 weeks
42
Table IV: Average days to maturation:Study ID Sample
sizeAverage number of days
Mean (95%CI)
Weighted SD
Cohort
Kybartiene, 2010Garcia Cortes, 2005
288 22.62 (21.26-23.99) 11.81 AVF, unspecified location. Overall.
Garcia Cortes, 2005
17 69.70 (51.64-87.76) 38.00 AVF, unspecified location. Age >75.
Rao, 2004Yilmaz, 2007Fitzgerald, 2004
119 92.55 (85.23- 99.88) 40.80 Brachial- basilic fistula.
Hruby, 2013Vahedian, 2012Alhassan, 2013
181 40.30 (38.72-41.88) 10.85 Radiocephalic fistula. Overall
Alhassan, 2013 97 30.80(28.57-33.03) 11.20 Radiocephalic fistula. Left hand.
43
Table V: Summary results of meta-analysis of included comparative studies per access types:
5.1: AVF, unspecified location:Study ID Cohort 1 Cohort 2 Results
Persic, 2013 Age ≥65. DM Age ≥65. No DM Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.5 (0.26-0.96)Secondary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.51 (0.21-1.22)
Segal, 2003 BMI ≥30 BMI <30 Primary patency in Cohort 1 > Cohort 2. Not statistically significant, RR 1.09 (0.56-2.13)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.73 (0.34-1.54)
Ferring, 2010 No Cardiac disease Cardiac disease Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.033 (0.597-1.788)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.037 (0.555-1.936)
Ferring, 2010 non-Caucasian Caucasian Primary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.951 (0.579-1.564)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.364 (0.782-2.380)
44
Ferring, 2010 No DM DM Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.504 (0.965-2.344)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.657 (0.989-2.777)
Ferring, 2010. Segal, 2003
Women Men Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.607 (0.421-0.876)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.590 (0.254-1.369)
Segal, 2003 Coronary artery disease (CAD) No CAD Primary patency in Cohort 1 > Cohort 2. Statistically significant, RR 2.5 (1.08-5.56)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, RR 1.49 (0.58-3.85)
Segal, 2003 DM No DM Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.7 (0.37-1.33)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.93 (0.41-2.08)
Segal, 2003 Previous access No Previous access Primary patency in Cohort 1 < Cohort 2. Statistically significant, RR 0.49 (0.26-0.92)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.47 (0.22-1.02)
45
Segal, 2003 Smoking No Smoking Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.81 (0.38-1.67)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.53 (0.21-1.32)
Segal, 2003 Black Non black Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.56 (0.17-1.85)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.45 (0.12-1.75)
Ferring, 2010 Not yet on hemodialysis On hemodialysis Primary patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.196 (1.323-3.644)Assisted patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.601 (1.473-4.594)
V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:Study ID Cohort 1 Cohort 2 ResultsIlhan, 2013. Lukowsky, 2012. Desilva, 2012
No subgroup reported. No subgroup reported. Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.839 (0.421-1.675)
Desilva, 2012 African American African American Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.63 (0.56-0.72)
Desilva, 2012 Age >90 Age >90 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.69 (0.52-0.91)
46
Desilva, 2012 Age 70 - 80 Age 70 - 80 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.56 (0.52-0.60)
Desilva, 2012 Age 81 - 90 Age 81 - 90 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.55 (0.51-0.59)
Desilva, 2012 Asian Asian Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.50 (0.37-0.67)
Desilva, 2012 Comorbidity index 1 (0-8) Comorbidity index 1 (0-8) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.52 (0.49-0.56)
Desilva, 2012 Comorbidity index 2 (=9) Comorbidity index 2 (=9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.61 (0.55-0.68)
Desilva, 2012 Comorbidity index 3 (>9) Comorbidity index 3 (>9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.57 (0.52-0.63)
Desilva, 2012 DM DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.58 (0.54-0.62)
Desilva, 2012 Women Women Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.59 (0.54-0.64)
Desilva, 2012 Men Men Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.51-0.57)
Desilva, 2012 Native American Native American Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.73 (0.40-1.32)
47
Desilva, 2012 No DM No DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.53 (0.50-0.57)
Desilva, 2012 White White Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.52-0.58)
V.3: Forearm AVF VS. Upper-arm AVF:Study ID Cohort 1 Cohort 2 ResultsFerring, 2010 Forearm AVF Upper-arm AVF Primary patency in Cohort 1 < Cohort
2. Statistically significant, HR 0.448 (0.277-0.724)Assisted patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.491 (0.284-0.849)
V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:Study ID Cohort 1 Cohort 2 ResultsWoo, 2012. Grubbs, 2013
Tunneled cuffed catheters, unspecified Autogenous upper extremity AVF, unspecified
Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 3.148 (0.774-12.808)
Foley, 2009 African American African American Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.19 (2.03-2.37)
Foley, 2009 Age >65 Age >65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.14 (2.06-2.23)
48
Foley, 2009 Age ≤65 Age ≤65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.31 (2.16-2.47)
Foley, 2009 Comorbid index ≥2 Comorbid index ≥2 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.03 (1.94–2.12)
Foley, 2009 Comorbid index 0 or 1 Comorbid index 0 or 1 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.37 (2.24–2.50)
Astor, 2005 Women Women Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.96 (0.50 to 1.87)
Foley, 2009 Hispanic Hispanic Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.23 (1.98-2.52)
Astor, 2005 Men Men Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.98 (1.16 to 3.38)
Foley, 2009 White White Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.18 (2.10-2.27)
V.5: AVG, unspecified location VS. AVF, unspecified location:Study ID Cohort 1 Cohort 2 ResultsWoo, 2012. Grubbs, 2013. Pisoni, 2009
No subgroup reported. No subgroup reported. Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.278 (1.139-1.435)
Foley, 2009 African American African American Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.33 (1.20-1.49)
49
Foley, 2009 Age > 65 Age >65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.36 (1.28-1.45)
Foley, 2009 Age ≤65 Age ≤65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.47 (1.32-1.63)
Foley, 2009 Comorbid index ≥2 Comorbid index ≥2 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.32(1.23–1.42)
Foley, 2009 Comorbid index 0 or 1 Comorbid index 0 or 1 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38(1.26–1.51)
Astor, 2005 Women Women Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.94 (0.51-1.72)
Foley, 2009 Hispanic Hispanic Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38 (1.13-1.67)
Astor, 2005 Men Men Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 1.29 (0.75-2.22)
Foley, 2009 White White Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.44 (1.35-1.54)
V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:Study ID Cohort 1 Cohort 2 Results
50
Goldfarb-Rumyantze, 2013Lukowsky, 2012Desilva, 2012
No subgroup reported. No subgroup reported. Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.922 (0.578-1.468)
Desilva, 2012 African American African American Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.77 (0.67-0.89)
Desilva, 2012 Age >90 Age >90 Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.83 (0.57-1.23)
Desilva, 2012 Age 70 - 80 Age 70 - 80 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.73 (0.66-0.80)
Desilva, 2012 Age 81 - 90 Age 81 - 90 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.74 (0.66-0.83)
Desilva, 2012 Asian Asian Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.67 (0.47-0.95)
Desilva, 2012 Comorbidity index 1 (0-8) Comorbidity index 1 (0-8) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.65 (0.58-0.73)
Desilva, 2012 Comorbidity index 2 (=9) Comorbidity index 2 (=9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.67-0.90)
Desilva, 2012 Comorbidity index 3 (>9) Comorbidity index 3 (>9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.85 (0.74-0.96)
Desilva, 2012 DM DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.71-0.86)
51
Desilva, 2012 Women Women Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.68 (0.61-0.75)
Desilva, 2012 Men Men Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.82 (0.74-0.91)
Desilva, 2012 Native American Native American Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.86 (0.27-2.73)
Desilva, 2012 No DM No DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.70 (0.62-0.78)
Desilva, 2012 White White Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.73 (0.67-0.80)
52
References:
1. Cante P, Bottet P, Ryckelynck JP, Roch BL, Levaltier B, Lobbedez T, et al. [Distal vascular access for chronic hemodialysis in
patients over 65 years of age. Surgical results]. Progres en Urologie. 1998;8(1):83-8.
2. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S.
hemodialysis patients. Kidney Int. 2001;60(4):1443-51.
3. Keuter XHA, Smet AAEAD, Kessels AGH, Sande FMvd, Welten RJTJ, Tordoir JHM. A randomized multicenter study of the
outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis.
Journal of Vascular Surgery. 2008;47(2):395-401.
4. Ayala MD, Smith RM, Martone C, Briggs W, Deitch JS, Wise L. The effect of systemic anticoagulation in patients undergoing
angioaccess surgery. Annals of Vascular Surgery. 2008;22(1):11-5.
5. Fassiadis N, Morsy M, Siva M, Marsh JE, Makanjuola AD, Chemla ES. Does the surgeon's experience impact on
radiocephalic fistula patency rates? Seminars in Dialysis. 2007;20(5):455-7.
6. Elwakeel HA, Saad EM, Elkiran YM, Awad I. Unusual vascular access for hemodialysis: transposed venae comitante of the
brachial artery. Annals of Vascular Surgery. 2007;21(5):560-3.
7. Keeling AN, Dwyer HO, Lyon S, Kelly PO, McGrath FP, Conlon PJ, et al. Do AshSplit haemodialysis catheters provide better
flow rates in the long term? Renal Failure. 2007;29(6):721-9.
53
8. Nikeghbalian S, Bananzadeh A, Yarmohammadi H. Difficult vascular access in patients with end-stage renal failure.
Transplantation Proceedings. 2006;38(5):1265-6.
9. Maya ID, Allon M. Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters.
Kidney International. 2005;68(6):2886-9.
10. Rooijens PPGM, Burgmans JPJ, Yo TI, Hop WCJ, Smet AAEAd, Dorpel MAvd, et al. Autogenous radial-cephalic or
prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the
patency of primary hemodialysis access. Journal of Vascular Surgery. 2005;42(3):481-6; discussions 7.
11. Madden RL, Lipkowitz GS, Browne BJ, Kurbanov A. A comparison of cryopreserved vein allografts and prosthetic grafts for
hemodialysis access. Annals of Vascular Surgery. 2005;19(5):686-91.
12. Chen JC, Kamal DM, Jastrzebski J, Taylor DC. Venovenostomy for outflow venous obstruction in patients with upper
extremity autogenous hemodialysis arteriovenous access. Annals of Vascular Surgery. 2005;19(5):629-35.
13. Akoh JA, Sinha S, Dutta S, Opaluwa AS, Lawson H, Shaw JF, et al. A 5-year audit of haemodialysis access. Int J Clin Pract.
2005;59(7):847-51.
14. Brueck M, Waeger S, Braig G, Kramer W. [Subcutaneously tunnelled cuffed venous hemodialysis catheters in chronic renal
failure]. Deutsche Medizinische Wochenschrift. 2004;129(47):2529-34.
15. Iorio BRD, Bellizzi V, Cillo N, Cirillo M, Avella F, Andreucci VE, et al. Vascular access for hemodialysis: the impact on
morbidity and mortality. Journal of Nephrology. 2004;17(1):19-25.
54
16. Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, et al. Basilic vein transposition fistula: a good option for
maintaining hemodialysis access site options? Journal of Vascular Surgery. 2004;39(5):1043-7.
17. Kao CL, Chang JP. The reverse upper arm curved graft with ringed PTFE graft as an alternative vascular access procedure for
hemodialysis. Journal of Cardiovascular Surgery. 2004;45(1):55-7.
18. Flarup S, Hadimeri H. Arteriovenous PTFE dialysis access in the lower extremity: a new approach. Annals of Vascular
Surgery. 2003;17(5):581-4.
19. Segal JH, Kayler LK, Henke P, Merion RM, Leavey S, Campbell DA, et al. Vascular access outcomes using the transposed
basilic vein arteriovenous fistula. American Journal of Kidney Diseases. 2003;42(1):151-7.
20. Gallieni M, Conz PA, Rizzioli E, Butti A, Brancaccio D. Placement, performance and complications of the Ash Split Cath
hemodialysis catheter. International Journal of Artificial Organs. 2002;25(12):1137-43.
21. Hingorani A, Ascher E, Kallakuri S, Greenberg S, Khanimov Y. Impact of reintervention for failing upper-extremity
arteriovenous autogenous access for hemodialysis. Journal of Vascular Surgery. 2001;34(6):1004-9.
22. Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance.
Journal of Vascular Surgery. 2001;34(5):866-71.
23. Vogel KM, Martino MA, Brien SPO, Kerstein MD. Complications of lower extremity arteriovenous grafts in patients with
end-stage renal disease. Southern Medical Journal. 2000;93(6):593-5.
55
24. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, et al. Predictors of adequacy of arteriovenous fistulas in
hemodialysis patients. Kidney International. 1999;56(1):275-80.
25. Khadra MH, Dwyer AJ, Thompson JF. Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for
hemodialysis access. American Journal of Surgery. 1997;173(4):280-3.
26. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL. Vascular access for hemodialysis. Patency
rates and results of revision. Annals of Surgery. 1985;202(2):235-9.
27. Rabbani A, Moini M, Shojaeefard A. Comparison between native arteriovenous fistula and graft in patients referred for
hemodialysis access placement. Acta Medica Iranica. 2006;44 (6):395-9.
28. Senkaya I, Aytac IK, Percin B, Bicer M. Basilic vein transposition a good choice for vascular access for A-V fistulas.
Chirurgia. 2006;19 (2):145-8.
29. Hood DB, Yellin AE, Richman MF, Weaver FA, Katz MD. Hemodialysis graft salvage with endoluminal stents. American
Surgeon. 1994;60 (10):733-7.
30. Brunori G, Verzelletti F, Zubani R, Movilli E, Gaggiotti M, Cancarini G, et al. Which vascular access for chronic hemodialysis
in uremic elderly patients? J Vasc Access. 2000;1(4):134-8.
31. Choi HM, Lal BK, Cerveira JJ, Padberg FT, Jr., Silva MB, Jr., Hobson RW, 2nd, et al. Durability and cumulative functional
patency of transposed and nontransposed arteriovenous fistulas. J Vasc Surg. 2003;38(6):1206-12.
56
32. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on
hemodialysis graft patency. N Engl J Med. 2009;360(21):2191-201.
33. Matsuura JH, Rosenthal D, Clark M, Shuler FW, Kirby L, Shotwell M, et al. Transposed basilic vein versus
polytetrafluorethylene for brachial-axillary arteriovenous fistulas. Am J Surg. 1998;176(2):219-21.
34. Silva MB, Jr., Hobson RW, 2nd, Pappas PJ, Jamil Z, Araki CT, Goldberg MC, et al. A strategy for increasing use of
autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg. 1998;27(2):302-7;
discussion 7-8.
35. Staramos DN, Lazarides MK, Tzilalis VD, Ekonomou CS, Simopoulos CE, Dayantas JN. Patency of autologous and prosthetic
arteriovenous fistulas in elderly patients. Eur J Surg. 2000;166(10):777-81.
36. Kokkosis AA, Abramowitz SD, Schwitzer J, Schanzer H, Teodorescu VJ. Experience of HeRO dialysis graft placement in a
challenging population. Vascular & Endovascular Surgery. 2013;47(4):278-80.
37. Goldfarb-Rumyantzev AS, Yoon JH, Patibandla BK, Narra A, Sandhu GS, Desilva R. The role of initial hemodialysis vascular
access in the outcome of subsequent kidney transplantation. Clinical Transplantation. 2013;27(2):210-6.
38. Al-Benna S, Deardon D, Hamilton D, El-Enin H. Long-term outcome of upper limb autogenous arteriovenous fistulas for
hemodialysis access. Saudi Journal of Kidney Diseases & Transplantation. 2013;24(1):109-14.
39. Sahin L, Gul R, Mizrak A, Deniz H, Sahin M, Koruk S, et al. Ultrasound-guided infraclavicular brachial plexus block
enhances postoperative blood flow in arteriovenous fistulas. Journal of Vascular Surgery. 2011;54(3):749-53.
57
40. Chiulli LC, Vasilas P, Dardik A. Superior patency of upper arm arteriovenous fistulae in high risk patients. Journal of Surgical
Research. 2011;170(1):157-64.
41. Bonforte G, Rossi E, Auricchio S, Pogliani D, Mangano S, Mandolfo S, et al. The middle-arm fistula as a valuable surgical
approach in patients with end-stage renal disease. Journal of Vascular Surgery. 2010;52(6):1551-6.
42. Ferring M, Claridge M, Smith SA, Wilmink T. Routine preoperative vascular ultrasound improves patency and use of
arteriovenous fistulas for hemodialysis: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN.
2010;5(12):2236-44.
43. Kybartiene S, Skarupskiene I, Ziginskiene E, Kuzminskis V. Vascular access for hemodialysis: creation, functioning, and
complications (data of the Hospital of Kaunas University of Medicine). Medicina (Kaunas, Lithuania). 2010;46(8):550-5.
44. Stuard S, Belcaro G, Dugall M, Cesarone MR, Hosoi M, Errichi BM, et al. Patency of arteriovenous fistula for dialysis
improbe with topical spraygel heparin. Panminerva Medica. 2010;52(2 Suppl 1):33-6.
45. Garcia Cortes MJ, Viedma G, Sanchez Perales MC, Borrego FJ, Borrego J, Perez del Barrio P, et al. [Fistulae or catheter for
elderly who start hemodialysis without permanent vascular access?]. Nefrologia. 2005;25(3):307-14.
46. Jimenez-Almonacid P, Rio JVD, Lasala M, Rueda JA, Vorwald P, Fernandez JM, et al. [First non-autologous vascular access
for hemodialysis: PTFE fistula]. Nefrologia. 2004;24(6):559-63.
47. Hernandez-Jaras J, Garcia-Perez H, Torregrosa E, Pons R, Calvo C, Serra M, et al. [Outcome of tunneled hemodialysis
catheters as permanent vascular access]. Nefrologia. 2004;24(5):446-52.
58
48. Rodriguez JA, Ferrer E, Olmos A, Codina S, Borrellas J, Piera L. [Analysis of the survival of permanent vascular access
ports]. Nefrologia. 2001;21(3):260-73.
49. Branger B, Reboul P, Prelipcean C, Noguera ME, Cariou S, Granolleras C, et al. [Tunnelled internal jugular vein catheters
with taurolidine lock: an acceptable challenge to arterio-venous fistula in 70 years old haemodialyzed patients: a prospective pilot
study]. Nephrologie et Therapeutique. 2011;7(4):237-41.
50. Kennealey PT, Elias N, Hertl M, Ko DSC, Saidi RF, Markmann JF, et al. A prospective, randomized comparison of bovine
carotid artery and expanded polytetrafluoroethylene for permanent hemodialysis vascular access. Journal of Vascular Surgery.
2011;53(6):1640-8.
51. Diehm N, Berg JCvd, Schnyder V, Buhler J, Willenberg T, Widmer M, et al. Determinants of haemodialysis access survival.
Vasa. 2010;39(2):133-9.
52. Wasse H, Speckman RA, McClellan WM. Arteriovenous fistula use is associated with lower cardiovascular mortality
compared with catheter use among ESRD patients. Seminars in Dialysis. 2008;21(5):483-9.
53. Ko PJ, Liu YH, Hung YN, Hsieh HC. Patency rates of cuffed and noncuffed extended polytetrafluoroethylene grafts in dialysis
access: a prospective, randomized study. World Journal of Surgery. 2009;33(4):846-51.
54. Slayden GC, Spergel L, Jennings WC. Secondary arteriovenous fistulas: converting prosthetic AV grafts to autogenous
dialysis access. Seminars in Dialysis. 2008;21(5):474-82.
59
55. Ekbal NJ, Swift PA, Chalisey A, Steele M, Makanjuola D, Chemla E. Hemodialysis access-related survival and morbidity in
an elderly population in South West Thames, UK. Hemodialysis International. 2008;12 Suppl 2:S15-9.
56. Tsoulfas G, Hertl M, Ko DSC, Elias N, Delmonico FL, Romano L, et al. Long-term outcome of a cuffed expanded PTFE graft
for hemodialysis vascular access. World Journal of Surgery. 2008;32(8):1827-31.
57. Long B, Bruyere F, Lermusiaux P, Culty T, Boutin JM, Artru B, et al. [Management of perianastomotic stenoses complicating
vascular accesses for haemodialysis]. Progres en Urologie. 2008;18(7):462-9.
58. Qasaimeh GR, Qaderi SE, Omari GA, Badadweh MA. Vascular access infection among hemodialysis patients in Northern
Jordan: incidence and risk factors. Southern Medical Journal. 2008;101(5):508-12.
59. Bronder CM, Cull DL, Kuper SG, Carsten CG, Kalbaugh CA, Cass A, et al. Fistula elevation procedure: experience with 295
consecutive cases during a 7-year period. Journal of the American College of Surgeons. 2008;206(5):1076-81; discussion 81-2.
60. Torina PJ, Westheimer EF, Schanzer HR. Brachial vein transposition arteriovenous fistula: is it an acceptable option for
chronic dialysis vascular access? Journal of Vascular Access. 2008;9(1):39-44.
61. Shahnawaz, Ali S, Shahzad I, Baloch MU. Arterio venous fistula experience at a tertiary care hospital in Pakistan. Pakistan
Journal of Medical Sciences. 2013;29 (1):161-5.
62. Morale W, Patane D, Incardona C, Seminara G, Messina M, Malfa P, et al. Venae comitantes as a potential vascular resource
to create native arteriovenous fistulae. Journal of Vascular Access. 2011;12 (3):211-4.
60
63. Lee ES, Shen Q, Pitts RL, Guo M, Wu MH, Sun SC, et al. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase
tissue inhibitors in patients are associated with arteriovenous fistula maturation. Journal of Vascular Surgery. 2011;54 (2):454-60.
64. Moussavi SR, Tofigh AM. Comparing the saphenous vein with the Gore-tex bridge fistula in thigh for chronic hemodialysis.
European Surgery - Acta Chirurgica Austriaca. 2007;39 (6):355-8.
65. Savader SJ, Haikal LC, Ehrman KO, Porter DJ, Oteham AC. Hemodialysis catheter-associated fibrin sheaths: Treatment with a
low-dose rt-PA infusion. Journal of Vascular and Interventional Radiology. 2000;11 (9):1131-6.
66. Hurlbert SN, Mattos MA, Henretta JP, Ramsey DE, Barkmeier LD, Hodgson KJ, et al. Long-term patency rates, complications
and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: A prospective study that compares Impra
versus Gore-tex grafts. Cardiovascular Surgery. 1998;6 (6):652-6.
67. McLaughlin K, Jones B, Mactier R, Porteus C. Long-term vascular access for hemodialysis using silicon dual-lumen catheters
with guidewire replacement of catheters for technique salvage. American Journal of Kidney Diseases. 1997;29 (4):553-9.
68. Ozlem N, Karakayali S, Aydin R, Tibet HB. A new method of AV fistula construction in chronic hemodialysis patients: 'Distal
snuffbox' AV fistulas. Dialysis and Transplantation. 1996;25 (2):82-6.
69. Tedoriya T, Urayama H, Katada S, Watanabe Y. A survey of vascular access for hemodialysis. Vascular Surgery. 1995;29
(2):123-7.
70. Beigi AA, Masoudpour H, Alavi M. The effect of ligation of the distal vein in snuff-box arteriovenous fistula. Saudi journal of
kidney diseases and transplantation. 2009;20(6):1110-4.
61
71. Gormus N, Ozergin U, Durgut K, Yuksek T, Solak H. Comparison of autologous basilic vein transpositions between forearm
and upper arm regions. Annals of Vascular Surgery. 2003;17(5):522-5.
72. Polo JR, Ligero JM, Diaz-Cartelle J, Garcia-Pajares R, Cervera T, Reparaz L. Randomized comparison of 6-mm straight grafts
versus 6- to 8-mm tapered grafts for brachial-axillary dialysis access. Journal of Vascular Surgery. 2004;40(2):319-24.
73. Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y, Fodera M, et al. Changes in the practice of angioaccess surgery:
impact of dialysis outcome and quality initiative recommendations. J Vasc Surg. 2000;31(1 Pt 1):84-92.
74. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. Type of vascular access and survival among incident
hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Journal of the American Society of
Nephrology : JASN. 2005;16(5):1449-55.
75. Coburn MC, Carney WI, Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc
Surg. 1994;20(6):896-902; discussion 3-4.
76. Haimov M, Burrows L, Schanzer H, Neff M, Baez A, Kwun K, et al. Experience with arterial substitutes in the construction of
vascular access for hemodialysis. The Journal of cardiovascular surgery. 1980;21(2):149-54.
77. Hazinedaroglu SM, Tuzuner A, Ayli D, Demirer S, Duman N, Yerdel MA. Femoral vein transposition versus femoral loop
grafts for hemodialysis: a prospective evaluation. Transplant Proc. 2004;36(1):65-7.
78. Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded
polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg. 1986;152(2):238-43.
62
79. Kim YS, Yang CW, Jin DC, Ahn SJ, Chang YS, Yoon YS, et al. Comparison of peritoneal catheter survival with fistula
survival in hemodialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
1995;15(2):147-51.
80. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ. Comparison of transposed brachiobasilic fistulas to upper
arm grafts and brachiocephalic fistulas. Kidney Int. 2001;60(4):1532-9.
81. Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM. Superiority of autogenous arteriovenous
hemodialysis access: maintenance of function with fewer secondary interventions. Ann Vasc Surg. 2004;18(1):66-73.
82. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis.
Journal of the American Society of Nephrology : JASN. 2004;15(2):477-86.
83. Ridao-Cano N, Polo JR, Polo J, Perez-Garcia R, Sanchez M, Gomez-Campdera FJ. Vascular access for dialysis in the elderly.
Blood Purif. 2002;20(6):563-8.
84. Sparks SR, VanderLinden JL, Gnanadev DA, Smith JW, Bunt TJ. Superior patency of perforating antecubital vein
arteriovenous fistulae for hemodialysis. Annals of Vascular Surgery. 1997;11 (2):165-7.
85. Tordoir JH, Kwan TS, Herman JM, Carol EJ, Jakimowicz JJ. Primary and secondary access surgery for haemodialysis with the
Brescia-Cimino fistula and the polytetrafluoroethylene (PTFE) graft. Neth J Surg. 1983;35(1):8-12.
63
86. Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent
cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. Journal of
Vascular Surgery. 1531;48(6):1524-31.
87. Flu H, Breslau PJ, Straaten JMK-v, Hamming JF, Lardenoye JWH. The effect of implementation of an optimized care protocol
on the outcome of arteriovenous hemodialysis access surgery. Journal of Vascular Surgery. 2008;48(3):659-68.
88. Kakkos SK, Haddad GK, Haddad RK, Scully MM. Effectiveness of a new tunneled catheter in preventing catheter
malfunction: a comparative study. Journal of Vascular & Interventional Radiology. 2008;19(7):1018-26.
89. Wu CC, Wen SC. Cutting balloon angioplasty for resistant venous stenoses of dialysis access: immediate and patency results.
Catheterization & Cardiovascular Interventions. 2008;71(2):250-4.
90. Kakkos SK, Andrzejewski T, Haddad JA, Haddad GK, Reddy DJ, Nypaver TJ, et al. Equivalent secondary patency rates of
upper extremity Vectra Vascular Access Grafts and transposed brachial-basilic fistulas with aggressive access surveillance and
endovascular treatment. Journal of Vascular Surgery. 2008;47(2):407-14.
91. Jean-Baptiste E, Hassen-Khodja R, Haudebourg P, Declemy S, Batt M, Bouillanne PJ. Axillary loop grafts for hemodialysis
access: midterm results from a single-center study. Journal of Vascular Surgery. 2008;47(1):138-43.
92. Schild AF, Perez EA, Gillaspie E, Patel AR, Noicely K, Baltodano N. Use of the Vectra polyetherurethaneurea graft for
dialysis access in HIV-positive patients with end-stage renal disease. Vascular & Endovascular Surgery. 2007;41(6):506-8.
64
93. Moossavi S, Regan JD, Pierson ED, Kasey JM, Tuttle AB, Vachharajani TJ, et al. Non-surgical salvage of thrombosed arterio-
venous fistulae: a case series and review of the literature. Seminars in Dialysis. 2007;20(5):459-64.
94. Woo K, Farber A, Doros G, Killeen K, Kohanzadeh S. Evaluation of the efficacy of the transposed upper arm arteriovenous
fistula: a single institutional review of 190 basilic and cephalic vein transposition procedures. Journal of Vascular Surgery.
2007;46(1):94-9; discussion 100.
95. Kayacioglu I, Baysal A, Ates M, Vural U, Balci AY, Saskin H, et al. The effect of the keyhole technique on diabetic patients
undergoing autologous brachiobasilic transposition of an arteriovenous fistula. Heart Surgery Forum. 2007;10(2):E147-52.
96. Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J
Am Soc Nephrol. 2007;18(6):1936-41.
97. Shemesh D, Goldin I, Berelowitz D, Zaghal I, Zigelman C, Olsha O. Blood flow volume changes in the maturing
arteriovenous access for hemodialysis. Ultrasound in Medicine & Biology. 2007;33(5):727-33.
98. Basaran O, Atac FB, Karakayali F, Aliosmanoglu I, Yagmurdur MC, Ozdemir FN, et al. Endothelial nitric oxide synthase gene
intron 4 (VNTR) polymorphism and vascular access graft thrombosis. Journal of Investigative Surgery. 2007;20(1):49-53.
99. Korten E, Toonder IM, Schrama YC, Hop WCJ, Ham ACvd, Wittens CHA. Dialysis fistulae patency and preoperative
diameter ultrasound measurements. European Journal of Vascular & Endovascular Surgery. 2007;33(4):467-71.
100. Yilmaz M, Senkaya I, Saba D, Bicer M. Long-term outcomes of basilic vein transposition fistula for hemodialysis. Vasa.
2007;36(1):29-32.
65
101. Mitchell D, Krishnasami Z, Young CJ, Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection.
Nephrology Dialysis Transplantation. 2007;22(2):465-70.
102. Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, et al. Relationship between clinical outcomes and
vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clinical Journal of The American Society
of Nephrology: CJASN. 2006;1(3):518-24.
103. Karakayali F, Basaran O, Ekici Y, Budakoglu I, Aytekin C, Boyvat F, et al. Effect of secondary interventions on patency of
vascular access sites for hemodialysis. European Journal of Vascular & Endovascular Surgery. 2006;32(6):701-9.
104. Sayed HFE, Mendoza B, Meier GH, LeSar CJ, DeMasi RJ, Glickman MH, et al. Utility of basilic vein transposition for
dialysis access. Vascular. 2005;13(5):268-74.
105. Fitzgerald JT, Schanzer A, McVicar JP, Chin AI, Perez RV, Troppmann C. Upper arm arteriovenous fistula versus forearm
looped arteriovenous graft for hemodialysis access: a comparative analysis. Annals of Vascular Surgery. 2005;19(6):843-50.
106. Modarai B, Dasgupta P, Taylor J, Koffman G, Khan MS. Follow-up of polytetrafluoroethylene arteriovenous fistulae for
haemodialysis. International Journal of Clinical Practice. 2005;59(9):1005-7.
107. Kizilisik AT, Kim SB, Nylander WA, Shaffer D. Improvements in dialysis access survival with increasing use of arteriovenous
fistulas in a Veterans Administration medical center. American Journal of Surgery. 2004;188(5):614-6.
108. Ko PJ, Hsieh HC, Chu JJ, Lin PJ, Liu YH. Patency rates and complications of Exxcel yarn-wrapped polytetrafluoroethylene
grafts versus Gore-tex stretch polytetrafluoroethylene grafts: a prospective study. Surgery Today. 2004;34(5):409-12.
66
109. Fitzgerald JT, Schanzer A, Chin AI, McVicar JP, Perez RV, Troppmann C. Outcomes of upper arm arteriovenous fistulas for
maintenance hemodialysis access. Archives of Surgery. 2004;139(2):201-8.
110. Mazzoni G, Frattarelli D, Iafrancesco D, Vagni V, Morosetti M, Farao RM. [Arteriovenous brachio-basilic fistula as
hemodialysis port. Original technique and long term results]. Giornale di Chirurgia. 2003;24(10):371-6.
111. Senkaya I, Aytac II, Eercan AK, Aliosman A, Percin B. The graft selection for haemodialysis. Vasa. 2003;32(4):209-13.
112. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly
Medicare ESRD patients. American Journal of Kidney Diseases. 2003;42(5):1013-9.
113. Shenoy S, Miller A, Petersen F, Kirsch WM, Konkin T, Kim P, et al. A multicenter study of permanent hemodialysis access
patency: beneficial effect of clipped vascular anastomotic technique. Journal of Vascular Surgery. 2003;38(2):229-35.
114. Bruns SD, Jennings WC. Proximal radial artery as inflow site for native arteriovenous fistula. Journal of the American College
of Surgeons. 2003;197(1):58-63.
115. Wiese P, Blume J, Mueller HJ, Renner H, Nonnast D, Barbara. Clinical and Doppler ultrasonography data of a polyurethane
vascular access graft for haemodialysis: a prospective study. Nephrology Dialysis Transplantation. 2003;18(7):1397-400.
116. Baldrati L, Pascalis AD, Giudicissi A, Docci D, Neri L, Feletti C. [Pre-dialysis arteriovenous fistula results in better patency
rate]. Giornale Italiano di Nefrologia. 2003;20(2):166-9.
117. Hossny A. Brachiobasilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-
related complications. Journal of Vascular Surgery. 2003;37(4):821-6.
67
118. Dalman RL, Harris EJ, Jr, Victor BJ, Coogan SM. Transition to all-autogenous hemodialysis access: the role of preoperative
vein mapping. Annals of Vascular Surgery. 2002;16(5):624-30.
119. Sorom AJ, Hughes CB, McCarthy JT, Jenson BM, Prieto M, Panneton JM, et al. Prospective, randomized evaluation of a
cuffed expanded polytetrafluoroethylene graft for hemodialysis vascular access. Surgery. 2002;132(2):135-40.
120. Ascher E, Hingoran A, Gunduz Y, Yorkovich Y, Ward M, Miranda J, et al. The value and limitations of the arm cephalic and
basilic vein for arteriovenous access. Ann Vasc Surg. 2001;15(1):89-97.
121. Wolowczyk L, Williams AJ, Donovan KL, Gibbons CP. The snuffbox arteriovenous fistula for vascular access. European
Journal of Vascular & Endovascular Surgery. 2000;19(1):70-6.
122. Taylor SM, Eaves GL, Weatherford DA, McAlhany JC, Jr, Russell HE, et al. Results and complications of arteriovenous
access dialysis grafts in the lower extremity: a five year review. American Surgeon. 1996;62(3):188-91.
123. Helling TS, Nelson PW, Shelton L. A prospective evaluation of plasma-TFE and expanded PTFE grafts for routine and early
use as vascular access during hemodialysis. Annals of Surgery. 1992;216(5):596-9.
124. Nannery WM, Stoldt HS, Fares LG, nd. Hemodialysis access operations performed upon patients with human
immunodeficiency virus. Surgery, Gynecology & Obstetrics. 1991;173(5):387-90.
125. Donnelly PK, Hoenich NA, Lennard TW, Proud G, Taylor RM. Surgical management of long-term central venous access in
uraemic patients. Nephrology Dialysis Transplantation. 1988;3(1):57-65.
68
126. Rizzuti RP, Hale JC, Burkart TE. Extended patency of expanded polytetrafluoroethylene grafts for vascular access using
optimal configuration and revisions. Surgery, Gynecology & Obstetrics. 1988;166(1):23-7.
127. Elwakeel H, Khafagy T, Regal S, Saad E. Prosthetic axillary-axillary arm loop arteriovenous graft for hemodialysis.
International Angiology. 2013;32(6):589-92.
128. Nadeau-Fredette AC, Goupil R, Montreuil B, Carignan A, Leblanc M. Arteriovenous fistula for the 80 years and older patients
on hemodialysis: is it worth it? Hemodialysis International. 2013;17(4):594-601.
129. Scarritt T, Paragone CM, Gorman RBO, Kyriazis DK, Maltese C, Rostas JW, et al. Traditional versus early-access grafts for
hemodialysis access: a single-institution comparative study. American Surgeon. 2014;80(2):155-8.
130. Hruby Z, Stanek-Piotrowska M, Turek J, Witkiewicz W, Jonkisz A, Konieczny A, et al. The clinicopathological determinants
of native arteriovenous fistula failure in patients on maintenance hemodialysis. Advances in Clinical & Experimental Medicine.
2013;22(4):495-500.
131. Kanko M, Sen C, Yavuz S, Unal C, Aksoy A, Berki T. Evaluation of arteriovenous fistulas made with the diamond-shaped
anastomosis technique. Medical Science Monitor. 2012;18(9):MT67-70.
132. Gage SM, Katzman HE, Ross JR, Hohmann SE, Sharpe CA, Butterly DW, et al. Multi-center experience of 164 consecutive
Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment. European Journal of Vascular & Endovascular
Surgery. 2012;44(1):93-9.
69
133. Basel H, Ekim H, Odabasi D, Kiymaz A, Aydin C, Dostbil A. Basilic vein transposition fistulas versus prosthetic bridge grafts
in patients with end-stage renal failure. Annals of Vascular Surgery. 2011;25(5):634-9.
134. Walker SR. U Clips for arteriovenous anastomosis: a pilot, randomized study. ANZ Journal of Surgery. 2012;82(9):630-2.
135. Huddam B, Azak A, Kocak G, Ortabozkoyun L, Duranay M. The efficacy of prophylactic antibiotics administration prior to
insertion of tunneled catheter in hemodialysis patients. Renal Failure. 2012;34(8):998-1001.
136. Woo K, Yao J, Selevan D, Hye RJ. Influence of vascular access type on sex and ethnicity-related mortality in hemodialysis-
dependent patients. Perm J. 2012;16(2):4-9.
137. Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Patterns and predictors of early mortality in incident
hemodialysis patients: new insights. American Journal of Nephrology. 2012;35(6):548-58.
138. Solid CA, Carlin C. Timing of arteriovenous fistula placement and Medicare costs during dialysis initiation. American Journal
of Nephrology. 2012;35(6):498-508.
139. Matsumoto H, Yamamoto E, Kamiya C, Miura E, Kitaoka T, Suzuki J, et al. Early use of brachial-basilic arteriovenous fistula.
Journal of Vascular Access. 2012;13(2):251-5.
140. DeSilva RN, Sandhu GS, Garg J, Goldfarb-Rumyantzev AS. Association between initial type of hemodialysis access used in
the elderly and mortality. Hemodialysis International. 2012;16(2):233-41.
141. Vahedian J, Jalayifar AM, Keramati MR, Nabavizadeh F, Vahedian M. Primary success of bifurcated vein patch arteriovenous
fistula and Brescia-Cimino methods. Iranian journal of Kidney Diseases. 2012;6(2):124-8.
70
142. Jackson RS, Sidawy AN, Amdur RL, Khetarpal A, Macsata RA. Angiotensin receptor blockers and antiplatelet agents are
associated with improved primary patency after arteriovenous hemodialysis access placement. Journal of Vascular Surgery.
2011;54(6):1706-12.
143. Chan KE, Pflederer TA, Steele DJR, Lilly MP, Ikizler TA, Maddux FW, et al. Access survival amongst hemodialysis patients
referred for preventive angiography and percutaneous transluminal angioplasty. Clinical Journal of The American Society of
Nephrology: CJASN. 2011;6(11):2669-80.
144. Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH. Influence of diabetes and perivascular allogeneic
endothelial cell implants on arteriovenous fistula remodeling. Journal of Vascular Surgery. 2011;54(5):1383-9.
145. Powell S, Chan TY, Bhat R, Lam K, Narlawar RS, Cullen N, et al. A retrospective comparative study of tunneled
haemodialysis catheters inserted through occluded or collateral veins versus conventional methods. Cardiovascular & Interventional
Radiology. 2010;33(4):744-50.
146. Karakayali F, Ekici Y, Gorur SK, Arat Z, Boyvat F, Karakayali H, et al. The value of preoperative vascular imaging in the
selection and success of hemodialysis access. Annals of Vascular Surgery. 2007;21(4):481-9.
147. Hamida FB, Hibik SM, Karoui C, Abderrahim E, Kaaroud H, Beji S, et al. [Indications, complications and cost of internal
jugular catheters in hemodialysed patients: study of 533 cases]. Tunisie Medicale. 2005;83(9):519-23.
148. Cetinkaya R, Odabas AR, Unlu Y, Selcuk Y, Ates A, Ceviz M. Using cuffed and tunnelled central venous catheters as
permanent vascular access for hemodialysis: a prospective study. Renal Failure. 2003;25(3):431-8.
71
149. Gorski TF, Gorski YC, Muney J. Complications of hemodialysis access in HIV-positive patients. American Surgeon.
2002;68(12):1104-6.
150. Ravani P, Marcelli D, Malberti F. Vascular access surgery managed by renal physicians: the choice of native arteriovenous
fistulas for hemodialysis. American Journal of Kidney Diseases. 2002;40(6):1264-76.
151. Bacchini G, Vecchio LD, Andrulli S, Pontoriero G, Locatelli F. Survival of prosthetic grafts of different materials after
impairment of a native arteriovenous fistula in hemodialysis patients. ASAIO Journal. 2001;47(1):30-3.
152. Friedman AL, Walworth C, Meehan C, Wander H, Shemin D, DeSoi W, et al. First hemodialysis access selection varies with
patient acuity. Advances in Renal Replacement Therapy. 2000;7(4 Suppl 1):S4-10.
153. Leapman SB, Boyle M, Pescovitz MD, Milgrom ML, Jindal RM, Filo RS. The arteriovenous fistula for hemodialysis access:
gold standard or archaic relic? American Surgeon. 1996;62(8):652-6; discussion 6-7.
154. Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC. Improved treatment of thrombosed hemodialysis access sites with
thrombolysis and angioplasty. Kidney International. 1994;46(5):1375-80.
155. Viron B, Lukacs B, Michel C, Thibault P, Mignon F. [Prosthesis without puncture, 3d generation of vascular access for
hemodialysis: a study of Hemasite in 10 patients]. Nephrologie. 1987;8(5):261-6.
156. Weale AR, Bevis P, Neary WD, Boyes S, Morgan JD, Lear PA, et al. Radiocephalic and brachiocephalic arteriovenous fistula
outcomes in the elderly. Journal of Vascular Surgery. 2008;47 (1):144-50.
72
157. Gargiulo M, Freyrie A, Faggioli GL, Tarantini S, Mosconi G, Santoro A, et al. Humeral-cephalic graft fistula in patients
requiring hemodialysis. Giornale Italiano di Chirurgia Vascolare. 1999;6 (4):269-79.
158. Mortazavi M, Alsaeidi S, Sobhani R, Salimic F, Atapour A, Sharif N, et al. Successful prevention of tunneled, central catheter
infection by antibiotic lock therapy using cefotaxime. Journal of Research in Medical Sciences. 2011;16(3):303-9.
159. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of
revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal
Data System Dialysis Morbidity and Mortality Study. J Vasc Surg. 2001;34(4):694-700.
160. Taylor B, Sigley RD, May KJ. Fate of infected and eroded hemodialysis grafts and autogenous fistulas. Am J Surg.
1993;165(5):632-6.
161. Morosetti M, Cipriani S, Dominijanni S, Pisani G, Frattarelli D, Bruno F. Basilic vein transposition versus biosynthetic
prosthesis as vascular access for hemodialysis. J Vasc Surg. 2011;54(6):1713-9.
162. Chen HY, Chiu YL, Chuang YF, Hsu SP, Pai MF, Lai CF, et al. Association of low serum fetuin A levels with poor
arteriovenous access patency in patients undergoing maintenance hemodialysis. American Journal of Kidney Diseases.
2010;56(4):720-7.
163. Gonzalez E, Kashuk JL, Moore EE, Linas S, Sauaia A. Two-stage brachial-basilic transposition fistula provides superior
patency rates for dialysis access in a safety-net population. Surgery. 2010;148(4):687-93; discussion 93-4.
73
164. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of
arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-71.
165. Louridas G, Botha JR, Levien L, Milne FJ, Meyers AM, Myburgh JA. Vascular access for haemodialysis--experience at
Johannesburg Hospital. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1984;66(17):637-40.
166. Foley RN, Chen SC, Collins AJ. Hemodialysis access at initiation in the United States, 2005 to 2007: still "catheter first".
Hemodialysis International. 2009;13(4):533-42.
167. Salman L, Alex M, Unger SW, Contreras G, Lenz O, Asif A. Secondary autogenous arteriovenous fistulas in the "fistula first"
era: results of a longterm prospective study. Journal of the American College of Surgeons. 2009;209(1):100-5.
168. Bradbury BD, Chen F, Furniss A, Pisoni RL, Keen M, Mapes D, et al. Conversion of vascular access type among incident
hemodialysis patients: description and association with mortality. American Journal of Kidney Diseases. 2009;53(5):804-14.
169. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, et al. Facility hemodialysis vascular access use and
mortality in countries participating in DOPPS: an instrumental variable analysis. American Journal of Kidney Diseases.
2009;53(3):475-91.
170. Bhomi KK, Shrestha S, Bhattachan CL. Role of systemic anticoagulation in patients undergoing vascular access surgery.
Nepal Medical College Journal: NMCJ. 2008;10(4):222-4.
171. Grubbs V, Wasse H, Vittinghoff E, Grimes BA, Johansen KL. Health status as a potential mediator of the association between
hemodialysis vascular access and mortality. Nephrol Dial Transplant. 2014;29(4):892-8.
74
172. Jemcov TK. Morphologic and functional vessels characteristics assessed by ultrasonography for prediction of radiocephalic
fistula maturation. Journal of Vascular Access. 2013;14(4):356-63.
173. Alhassan SU, Adamu B, Abdu A, Aji SA. Outcome and complications of permanent hemodialysis vascular access in
Nigerians: a single centre experience. Annals of African Medicine. 2013;12(2):127-30.
174. Ilhan G, Esi E, Bozok S, Yurekli I, Ozpak B, Ozelci A, et al. The clinical utility of vascular mapping with Doppler ultrasound
prior to arteriovenous fistula construction for hemodialysis access. Journal of Vascular Access. 2013;14(1):83-8.
175. Manson RJ, Ebner A, Gallo S, Chemla E, Mantell M, Deaton D, et al. Arteriovenous fistula creation using the Optiflow
vascular anastomosis device: a first in man pilot study. Seminars in Dialysis. 2013;26(1):97-9.
176. Wongkonkitsin N, Prasertcharoensuk S. Patency of vascular accesses for Thai hemodialysis patients. J Med Assoc Thai.
2014;97(3):317-21.
177. Watorek E, Golebiowski T, Kusztal M, Letachowicz K, Letachowicz W, Augustyniak Bartosik H, et al. Creation of
arteriovenous fistulae for hemodialysis in octogenarians. Hemodial. 2014;18(1):113-7.
178. Wetzig GA, Gough IR, Furnival CM. One hundred cases of arteriovenous fistula for haemodialysis access: the effect of
cigarette smoking on patency. Australian & New Zealand Journal of Surgery. 1985;55(6):551-4.
179. Hart D, Gooden C, Cummings LS, Wible BC, Borsa J, Randall H. Modification of the HeRO graft allowing earlier cannulation
and reduction in catheter dependent days in patients with end stage renal disease: A single center retrospective review. The Scientific
World Journal. 2014;2014(318629).
75
180. Persic V, Buturovic-Ponikvar J, Arnol M, Ponikvar R. Outcomes of native arteriovenous fistula in hemodialysis patients over
65 years of age. Nephrology Dialysis Transplantation. 2013;Conference: 50th ERA-EDTA Congress Istanbul Turkey. Conference
Start: 20130518 Conference End: 20130521. Conference Publication: (var.pagings). 28:i235.
181. Prischl FC, Kirchgatterer A, Brandstatter E, Wallner M, Baldinger C, Roithinger FX, et al. Parameters of prognostic relevance
to the patency of vascular access in hemodialysis patients. J Am Soc Nephrol. 1995;6(6):1613-8.
182. Kaufman JL, Garb JL, Berman JA, Rhee SW, Norris MA, Friedmann P. A prospective comparison of two expanded
polytetrafluoroethylene grafts for linear forearm hemodialysis access: does the manufacturer matter? J Am Coll Surg. 1997;185(1):74-
9.
183. Lok CE, Oliver MJ, Su J, Bhola C, Hannigan N, Jassal SV. Arteriovenous fistula outcomes in the era of the elderly dialysis
population. Kidney Int. 2005;67(6):2462-9.
184. Vaux E, King J, Lloyd S, Moore J, Bailey L, Reading I, et al. Effect of buttonhole cannulation with a polycarbonate PEG on
in-center hemodialysis fistula outcomes: a randomized controlled trial. Am J Kidney Dis. 2013;62(1):81-8.
185. Bender MH, Bruyninckx CM, Gerlag PG. The Gracz arteriovenous fistula evaluated. Results of the brachiocephalic elbow
fistula in haemodialysis angio-access. European journal of vascular and endovascular surgery : the official journal of the European
Society for Vascular Surgery. 1995;10(3):294-7.
186. Yasuhara H, Shigematsu H, Muto T. Results of arteriovenous fistula revision in the forearm. Am J Surg. 1997;174(1):83-6.
76
187. Wang SS, Chu SH. Clinical use of omniflow vascular graft as arteriovenous bridging graft for hemodialysis. Artif Organs.
1996;20(12):1278-81.
188. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW. A practical approach to vascular access for hemodialysis and
predictors of success. J Vasc Surg. 1999;30(4):727-33.
189. Elcheroth J, de Pauw L, Kinnaert P. Elbow arteriovenous fistulas for chronic haemodialysis. Br J Surg. 1994;81(7):982-4.
190. Simoni G, Bonalumi U, Civalleri D, Decian F, Bartoli FG. End-to-end arteriovenous fistula for chronic haemodialysis: 11
years' experience. Cardiovascular surgery. 1994;2(1):63-6.
191. Rubens F, Wellington JL. Brachiocephalic fistula: a useful alternative for vascular access in chronic hemodialysis.
Cardiovascular surgery. 1993;1(2):128-30.
192. Burt CG, Little JA, Mosquera DA. The effect of age on radiocephalic fistula patency. J Vasc Access. 2001;2(3):110-3.
193. Golledge J, Smith CJ, Emery J, Farrington K, Thompson HH. Outcome of primary radiocephalic fistula for haemodialysis. Br
J Surg. 1999;86(2):211-6.
194. Lemson MS, Tordoir JH, van Det RJ, Welten RJ, Burger H, Estourgie RJ, et al. Effects of a venous cuff at the venous
anastomosis of polytetrafluoroethylene grafts for hemodialysis vascular access. J Vasc Surg. 2000;32(6):1155-63.
195. Curi MA, Pappas PJ, Silva MB, Jr., Patel S, Padberg FT, Jr., Jamil Z, et al. Hemodialysis access: influence of the human
immunodeficiency virus on patency and infection rates. J Vasc Surg. 1999;29(4):608-16.
77
196. Munda R, First MR, Alexander JW, Linnemann CC, Jr., Fidler JP, Kittur D. Polytetrafluoroethylene graft survival in
hemodialysis. Jama. 1983;249(2):219-22.
197. Silva MB, Jr., Hobson RW, 2nd, Pappas PJ, Haser PB, Araki CT, Goldberg MC, et al. Vein transposition in the forearm for
autogenous hemodialysis access. J Vasc Surg. 1997;26(6):981-6; discussion 7-8.
198. Hakaim AG, Scott TE. Durability of early prosthetic dialysis graft cannulation: results of a prospective, nonrandomized
clinical trial. J Vasc Surg. 1997;25(6):1002-5; discussion 5-6.
199. Bone GE, Pomajzl MJ. Prospective comparison of polytetrafluoroethylene and bovine grafts for dialysis. The Journal of
surgical research. 1980;29(3):223-7.
200. Hibberd AD. Brachiobasilic fistula with autogenous basilic vein: surgical technique and pilot study. The Australian and New
Zealand journal of surgery. 1991;61(8):631-5.
78